Observational study found thrombotic risk and adverse cardiovascular outcomes in ICI-treated Hispanic adults, highlighting the need for targeted surveillance.
Key Points
To describe the incidence and predictors of major adverse cardiovascular events and thrombosis in immune checkpoint inhibitor-treated adults.
Conducted an observational retrospective study
Included adults treated with PD-1, PD-L1, or PD-1 + CTLA-4 inhibitors
Extracted data from electronic records
Utilized Kaplan–Meier for event-free survival estimation
Applied multivariable Cox regression for predictors assessment.
206 patients included with a median age of 66 years
MACE occurred in 10.2% primarily from myocardial infarction and heart failure
Thrombotic events reported in 14.1%, mainly venous
Combination therapy showed highest incidence of MACE (19.2%) and thrombosis (26.9%)
Significant predictor of thrombotic risk was concomitant chemotherapy.